Repeatability and Reproducibility of Multiparametric MRI

NCT ID: NCT03743272

Last Updated: 2025-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

61 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-03

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2\*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK) protocol across different field strengths, scanner manufacturers and models.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As the burden of liver disease reaches epidemic levels, there is a high unmet medical need to develop robust, accurate and reproducible non-invasive methods to quantify liver tissue characteristics for use in clinical development and ultimately in clinical practice. Repeatability and reproducibility validation studies are important in evaluating metrics, such that any changes can be confidently attributed to disease progression or regression, rather than inter-examination variability in the instrument.

Magnetic resonance (MR) techniques offer an attractive non-invasive option for liver assessment. Multiparametric MRI is a safe and non-invasive method for quantification of liver tissue characteristics. Images for quantification of hepatic fat from proton density fat fraction (PDFF) maps, T2\*, and iron-corrected T1 (cT1) can be rapidly obtained during abdominal breath-hold acquisitions without the need for contrast agents or additional external hardware. Iron correction of T1 is necessary to address the confounding effects of excess iron, which is common in chronic liver disease. LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK) is a software application that can be used with supported MR-systems to correct T1 for the effects of excess iron, and thus, to calculate cT1 from T1 and T2\* maps, and standardise to a 3T field strength.

This method has been shown to have high diagnostic accuracy for the assessment of liver fibrosis compared to histology, predict clinical outcomes in patients with mixed liver disease aetiology, stratify patients with non-alcoholic steatohepatitis (NASH) and cirrhosis, reliably exclude clinically significant liver disease and is cost-effective in diagnosing NAFLD.

In addition to demonstrating accuracy, imaging biomarker validation requires precision and repeatability (US Department of Health and Human Services, 2015). From a clinical perspective, it is essential to ensure that there is good inter-examination repeatability, so that any changes seen can be correctly attributed to disease progression or regression, rather than inter-examination variability. This is tested by examining the closeness of repeated measurements made in different MR examinations (with both subject and coil repositioning) over a time frame in which physiologic conditions are assumed constant.

This study aims to systematically test the repeatability and reproducibility of each multiparametric MRI measurement, cT1, T2\* and PDFF, corresponding to hepatic fibro-inflammation, iron and fat respectively, across scanner field strength, manufacturer and model in human participants and phantoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Diseases Primary Biliary Cirrhosis Non-Alcoholic Fatty Liver Disease Non-Alcoholic Steatohepatitis Cirrhosis Hemochromatosis Viral Hepatitis Autoimmune Hepatitis Primary Sclerosing Cholangitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver condition

Participants who have a history of of liver disease

LiverMultiScan

Intervention Type DEVICE

Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.

Healthy volunteers

Participants who have do not have a diagnosed liver condition and are in general good health

LiverMultiScan

Intervention Type DEVICE

Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LiverMultiScan

Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Multiparametric Magnetic Resonance Imaging (mpMRI)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any person over 18 years of age.
* Participant is willing and able to give informed consent.

Exclusion Criteria

* The participant may not enter the study if they have any contraindication to magnetic resonance imaging (inc pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia).
* Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study or affect the participant's ability to participate in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Perspectum

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rajarshi Banerjee, BM BCh MS DPhil

Role: PRINCIPAL_INVESTIGATOR

Perspectum Diagnostics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Leiden University Medical Centre

Leiden, , Netherlands

Site Status

Addenbrookes Hospital

Cambridge, Cambridgeshire, United Kingdom

Site Status

University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR)

Oxford, Oxfordshire, United Kingdom

Site Status

Southampton General Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Pickles E, Kumar S, Brady M, Telford A, Pavlides M, Bulte D. Comparison of liver iron concentration calculated from R2* at 1.5 T and 3 T. Abdom Radiol (NY). 2023 Mar;48(3):865-873. doi: 10.1007/s00261-022-03762-4. Epub 2022 Dec 15.

Reference Type DERIVED
PMID: 36520162 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LMSRR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CT Liver Fat Fraction Quantification
NCT05676177 ENROLLING_BY_INVITATION NA
LITMUS Imaging Study
NCT05479721 ACTIVE_NOT_RECRUITING
MRI in Portal Hypertension
NCT01756859 UNKNOWN